Search:
You do not have permission to access this chart.
Please Sign Up or Login
News for Protara Therapeutics, Inc. (TARA)
minutes ago | Banggood.com
58 minutes ago | Aliexpress.com
a week ago | GlobeNewsWire
2 months ago | GlobeNewsWire
3 months ago | GlobeNewsWire
3 months ago | Pulse2
3 months ago | GlobeNewsWire
3 months ago | GlobeNewsWire
3 months ago | GlobeNewsWire
5 months ago | GlobeNewsWire
6 months ago | GlobeNewsWire
8 months ago | GlobeNewsWire
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.